Inventiva (NASDAQ:IVA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Inventiva (NASDAQ:IVA) in a report issued on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Inventiva’s FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($2.43) EPS, FY2028 earnings at $0.49 EPS and FY2029 earnings at $3.19 EPS.

Other equities research analysts have also issued research reports about the company. Guggenheim lifted their price objective on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler started coverage on Inventiva in a research note on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.83.

Inventiva Stock Down 0.5%

Inventiva stock opened at $5.57 on Wednesday. Inventiva has a one year low of $1.53 and a one year high of $6.50. The business has a fifty day moving average price of $3.90 and a 200-day moving average price of $3.46.

Institutional Investors Weigh In On Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC grew its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 at the end of the most recent reporting period. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.